semaglutide + cilofexor + firsocostat

semaglutide + cilofexor + firsocostat is an investigational combination of three small molecule drugs targeting distinct but complementary pathways in the treatment of nonalcoholic steatohepatitis (NASH). Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that enhances insulin secretion and reduces appetite. Cilofexor is a selective, non-steroidal agonist of the farnesoid X receptor (FXR), a nuclear receptor that modulates bile acid, lipid, and glucose metabolism. Firsocostat is a liver-directed acetyl-coenzyme A carboxylase (ACC) inhibitor that reduces hepatic de novo lipogenesis. Recent phase II clinical trials evaluated the safety and efficacy of this triple combination in NASH patients with fibrosis, showing favorable safety and improved liver steatosis and biochemistry versus semaglutide alone. The agents are combined to address multiple complementary pathways implicated in NASH progression, with the goal of enhanced efficacy over monotherapy. Development for this combination is ongoing in phase II studies for NASH, including in patients with cirrhosis[1][8][10].

Other names

semaglutide + cilofexor + firsocostat combinationSEMA + CILO + FIR